Regeneration Achieved in 4 Weeks, Even for Elderly Patients with Compromised Skin Healing
North American Market Entry Accelerates, Building on Successful Commercialization in South America

ROKIT Healthcare (376900, CEO Seokhwan You), an AI-driven personalized organ regeneration platform specialist, is signaling a major paradigm shift in skin cancer (non-melanoma) regeneration, following its success with AI-driven diabetic foot ulcer regeneration.

The company officially unveiled its AI-based skin cancer regeneration platform at 'Plastic Surgery the Meeting (PSTM),' the world's most prestigious plastic surgery conference, which took place in New Orleans, Louisiana, from October 10-12. This event marks the acceleration of its North American market expansion.

The platform unveiled at the event is an innovative technology aiming for the 'Full Regeneration' of the skin defect, rather than just simple treatment. It is gaining significant industry attention for its clinical results, particularly in elderly patient groups. These patients, who typically have markedly reduced healing capabilities for defects caused by non-melanoma skin cancer, demonstrated skin regeneration in an average of just four weeks.

"ROKIT Healthcare’s AI-based regeneration platform is a groundbreaking solution for addressing complex skin defects that were difficult to treat with conventional methods," stated Professor James J. Yoo, M.D., Ph.D., of the Wake Forest University School of Medicine. "This technology not only significantly accelerates patient recovery but also provides excellent aesthetic outcomes, dramatically improving their quality of life.“

The platform utilizes AI to perform a 3D precision analysis of the skin defect following lesion excision. Based on this analysis, it then uses a 3D bioprinter to produce, transplant, and regenerate a personalized skin patch. The transplanted, AI-customized patch regenerates into identical skin tissue regardless of the patient's age, ethnicity, or skin color, achieving full restoration without side effects.

This technology has already been commercially validated in the South American market. It is currently generating revenue in Paraguay and is being applied in clinical settings in Chile and Argentina for patient treatment. Building on this proven success in three South American countries, ROKIT Healthcare plans to leverage PSTM as a pivotal moment for its global market expansion.

According to the market research firm IMARC, the global skin cancer 'regeneration' market is a 'blue ocean' sector. It was valued at approximately USD 400-700 million as of 2024 and is projected to exceed USD 900 million (approx. KRW 1.3 trillion) by 2030, expanding at a compound annual growth rate (CAGR) of nearly 10%.

ROKIT Healthcare is positioning itself to lead this market and establish a new global standard for skin cancer regeneration, backed by its unparalleled patented technology.
A company spokesperson stated, “Building on our commercial success in the South American market, we will accelerate our expansion into North America. We are committed to offering new hope—full regeneration without side effects—to patients worldwide suffering from skin cancer.”

▲Reference: Yun YK, Han SK, Yoon IJ, et al. (2024). Evaluating micronized adipose tissue niche and artificial dermis grafts following nonmelanoma skin cancer excision: a pilot study. Wounds, 36(4), 131. Figure 1.
▲Photo Description: After tumor excision (D), a 3D-printed micro-adipose tissue (MAT) graft was implanted (E), showing complete wound healing over a 5-week period (F–I).